David D. Halbert

North Texas’ Caris Life Sciences Eyes $5.3B Valuation in Its Nasdaq IPO

by | Jun 10, 2025
The Irving-based leader in precision oncology—which has raised $1.86 billion since 2018—plans to raise as much as $423.5 million when it goes public on the Nasdaq Global Select Market under the ticker symbol CAI.
MORE
Irving’s Caris Life Sciences Files for IPO, Backed by AI-Driven Precision Oncology Platform
by | May 28, 2025
With $1.86 billion raised since 2018 and recent product launches, the North Texas life science company founded in 2008 is preparing for a public debut on the Nasdaq Global Select Market, following a $168 million growth capital round in April.
MORE
Caris Life Sciences Raises $310M to Continue Rapidly Growing in the Precision Medicine Market
by | Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE